Research and Markets


Printer Friendly

Printed from http://www.researchandmarkets.com/reports/656053


The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2007)


Description: This report looks at the biotech industries in Europe, with a focus on France, Germany, Netherlands, Sweden, Switzerland and the United Kingdom
Current Environment - Key Points
- The European biotech sector as a whole fared well over the past six months, fueled by good news and further M&A speculation
- Following the acquisition of Serono (SWX: SEO) by Merck (NYSE: MRK) in September 2006, Merck announced the official launch of Merck Serono (SWX: SEO) on January 8 this year
Merck Serono will operate as a biotech division within the pharmaceuticals business sector of Merck
- Deal-making continued at a torrid pace in Europe over the past six months, with a long line of pharma companies increasingly willing to pay a premium for a stake in a promising therapeutic program
- In December 2006, GlaxoSmithKline (NYSE: GSK) broke an industry record by licensing a drug for leukemia from Genmab (CSE: GEN) for US$2.1 billion
In the same month GSK announced a deal to acquire private drug discovery outfit Domantis for US$453 million
- Biotech IPOs in Europe showed signs of improvement
Nine European biotech companies listed between September 2006 and March this year
The total amount raised was US$446.8 million, according to a Mergent analysis

Industry Profile - Key Points
- A report released in May by Critical I, a biotech industry consultancy, demonstrates a number of consequences arising from an insufficient and unsustainable stream of finance for biotechnology
The report put the respective number of companies in Europe and the US at 2,163 and 1,991
However, American biotechs are larger, better financed and more profitable
- There have been several important developments in healthcare biotechnology in the past year
They include the implementation of the Advanced Therapies Regulations, the completion of the biosimilars framework and the setting up of the European Medicines Agency's (EMEA) dedicated office for SMEs
- The Seventh Research Framework Program (FP7) which was adopted in December 2006 and applies to the 2007-2013 period will provide a significant contribution to the competitiveness of the European bio-industry
- In November 2006, the European Commission (EC) published new state aid rules recognizing Young Innovative Company (YIC) status
- There have been some small but encouraging signs of progress in the acceptance of green biotechnology in Europe
Five European countries grew genetically modified crops in 2006, with member states starting to adopt reasonable rules on co-existence
Market Trends and Outlook - Key Points
- The development of regenerative drugs for diseases such as cancer can be enhanced by using robotics to automate stem cell research
- Industrial biotech is gaining growing priority in Europe
The European Commission has introduced initiatives to promote the development of biorefineries in Europe
This was followed on December 14, 2006, with the publication by the European biotech industry of a new Industrial Biotechnology Policy Agenda for Europe
- European farmers are lagging behind the rest of the world in terms of access to agribiotech, according to the European Federation of Biotechnology
According to the International Service for the Acquisition of Agri-biotech Applications (ISAAA), most growth in biotech over the next ten years is expected to occur in key developing countries in Asia, led by China and India, as well as Pakistan and Vietnam


Contents: Current Environment
- Sector Overview
- Sector Performance
- Leading Companies
- Mergers, Acquisitions and
Alliances
- Initial Public Offerings
Industry Profile
- Sector Size and Value
- Industry Focus Areas
- Sector Investment
- Government Investment
- Policy and Regulatory
Environment
Market Trends and Outlook
- Robotics Could Speed Up Stem
Cell Research
- Industrial Biotech Grows
Importance in Europe
- European Farmers Loses Out in
Agribiotech Revolution
- Market Outlook
Country Profiles
- France
- Germany
- The Netherlands
- Sweden
- Switzerland
- United Kingdom
Currency Conversion Table
The Scope of This Report
Key References
Comparative Data
Reports Coverage




Ordering: Order Online - visit http://www.researchandmarkets.com/reports/656053

Order by Fax - using the order form below

Order By Post - print the order form below and send to

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


Research and Markets Page 1 of 2
Printed 16/02/2012 17:56:49
Fax Order Form
To place an order via fax simply print this form, fill in the information below and fax the completed form to
646-607-1907 (from USA) or +353 1 6849977 (from Rest of World). If you have any questions please email help@researchandmarkets.net

Order information
Please verify that the product information is correct and select the format you require.
Product Name:
The Europe Biotechnology Sectors : A Company and Industry Analysis (April 2007)
Web Address:
http://www.researchandmarkets.com/reports/656053
Office Code:
OC8IHINLSNNSS

Report formats
Please enter the quantity of the report format you require.

Format Quantity Price
Electronic (PDF) - Single User €200.00



Contact information
Please enter all the information below in BLOCK CAPITALS.

First Name:   Last Name:  
Email Address:
Job Title:
Organisation:
Address:
City:
Postal/Zip Code:
Country:
Phone Number:
Fax Number:


Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)
Research and Markets Page 2 of 2
Printed 16/02/2012 17:56:49

Payment information

Please indicate the payment method you would like to use by selecting the appropriate box.

 Pay by Credit Card:
American Express
Diners Club
Master Card
Visa
Cardholder's Name:
Cardholder's Signature:
Expiry Date: /
Card Number:
CVV Security Code:
Issue Date: /   (Diners Club only)


 Pay by Check:
Please post the check, accompanied by this form, to:

Research and Markets,
Guinness Centre,
Taylors Lane,
Dublin 8,
Ireland.


 Pay by Wire Transfer:
Please transfer funds to:

Account number: 83313083
Sort code: 98-53-30
Swift code: ULSBIE2D
IBAN number: IE78ULSB98533083313083
Bank Address: Ulster Bank,
27-35 Main St,
Blackrock,
Co. Dublin,
Ireland.
If you have a Marketing Code please enter it below:
Marketing Code:


Please note that by ordering from Research and Markets you are agreeing to our Terms and Conditions at http://www.researchandmarkets.com/info/terms.asp

Please fax this form to:
(646) 607-1907 or (646) 964-6609 (from USA)
+353-1-481-1716 or +353-1-653-1571 (from Rest of World)